No Data
Aohua Endoscopy (688212.SH): Shareholder Appalachian has cumulatively reduced its shareholding by 1.42%.
On November 14, Gelonghui reported that Auhua Endoscope (688212.SH) announced that the company received a notice from its shareholder Appalachian on November 13, 2024. As of the date of this announcement, Appalachian has reduced its shareholding by a total of 1,914,722 shares through centralized bidding and block trading, accounting for 1.42% of the company's total share capital. This shareholding reduction plan has been completed.
Australia China Endoscopy (688212.SH) 41.8228 million shares of restricted shares will be listed for trading starting November 15th.
Aohua Endoscopy (688212.SH) announced that the restricted shares to be listed for the first time are part of the company's initial public offering...
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.'s (SHSE:688212) Latest 6.0% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Olympus Endoscopy (688212.SH): Currently, overseas is still in the early stage.
Gelonghui on October 28th | Aohua Endoscopy (688212.SH) investor relations activity records show that due to its relatively small scale, the overseas market is still in the early stages. Since the beginning of this year, a series of products including the AQ-300 have been approved in multiple countries or regions, further developing access to overseas markets. The international marketing team is actively participating in various industry conferences and engaging in industry exchanges. Currently, the company's overseas markets are mainly located in Europe and other cost-effective markets. Both markets have increasing demand for soft lenses, so the company will continue to promote the development of overseas markets.
Third Quarter Report 2024
The reversal of previously recognized share-based payment expenses and significant increase in government subsidies led to a more than threefold increase in net income for Aohua Endoscopy in Q3.
Due to the third quarter reversal of previously recognized share-based payment expenses, coupled with large government subsidies, Aohua Endoscopy achieved a third-quarter net income attributable to the parent company of 31.6414 million yuan, a year-on-year increase of 345.17%. In the field of soft endoscopes where foreign manufacturers have a market monopoly, Aohua Endoscopy not only holds a place, but its products have also entered the markets of Germany, the united kingdom, south korea, and other countries.
There's Been No Shortage Of Growth Recently For Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Returns On CapitalNo Data
No Data
